Bristol-Myers will sell Opdivo in China at half of US cost, setting precedent for checkpoint wave — report

Bristol-Myers will sell Opdivo in China at half of US cost, setting precedent for checkpoint wave — report

Source: 
Endpoints
snippet: 

Bristol-Myers Squibb is continuing to set precedents in China with Opdivo, the first PD-1/L1 checkpoint approved in the country, as it reportedly prices the drug at around $84,000 per year — about half of its list price in the US.